

December 4, 2006

IN THIS ISSUE:

- **Update on (Tubersol® Lot # C2316AA)**

FROM:

Eileen de Villa, MD, MBA, MHSc, CCFP, FRCPC
Associate Medical Officer of Health

Introduction

On October 20th, 2006, Peel Public Health issued a Health Professionals Update advising healthcare providers to suspend use of Tubersol® with **Lot# C2316AA** due to an increased potential for anaphylactic reactions after administration.

At that time, Peel Public Health and the Ministry of Health and Long-Term Care (MOHLTC) advised healthcare providers to put aside Tubersol® with the **Lot# C2316AA**.

An investigation on this matter was conducted by Health Canada, and it was revealed that a significant proportion of the reported cases of serious allergic reactions associated with Tubersol® involved patients who had a history of allergic reactions to other allergens.

MOHLTC recommendations as of November 29, 2006:

- **Resume use of Tubersol® Lot# C2316AA with enhanced surveillance.**
- Keep Epinephrine Hydrochloride Solution (1:1000) and other appropriate agents available for immediate use in case an anaphylactic or other acute hypersensitivity reaction occurs.
- Monitor all patients for immediate reactions for a period of at least 15 minutes after inoculation (Canadian Immunization Guide, 2002).

- Report all reactions to Peel Public Health at (905) 799-7700.

For all other inquiries, please contact Peel Public Health at **(905) 799-7700**.